Related Experiment Video

Updated: Jun 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Emerging therapies in castrate-resistant prostate cancer

Luai Zarour1, Joshi Alumkal

  • 1Division of Hematology & Oncology, Department of Medicine, Oregon Health & Science University, 3303 SW Bond Avenue CH14R, Portland, OR, 97239, USA.

Current Urology Reports
|April 29, 2010
PubMed

Insights

Emerging therapies offer new hope for men with advanced prostate cancer. This review highlights novel treatments targeting castration-resistant prostate cancer progression and resistance to hormonal therapy.

Area of Science:

  • Oncology
  • Urology

Background:

  • Prostate cancer is the leading cause of cancer death in US men.
  • Castrate-resistant metastatic prostate cancer progresses despite hormonal therapy.
  • Understanding molecular mechanisms drives new treatment strategies.

Purpose of the Study:

  • To review emerging therapies for castrate-resistant prostate cancer (CRPC).
  • To emphasize the importance of drug targets in CRPC treatment.
  • To summarize the status of current clinical trials for CRPC.

Main Methods:

  • Literature review of emerging therapies for CRPC.
  • Focus on drug targets and clinical trial data.
  • Analysis of hormonal therapies, biological agents, and immunotherapy.

Main Results:

  • Recent advances have improved understanding of CRPC progression.
  • Novel therapeutic targets are being explored.
  • Clinical trials are evaluating new treatment modalities.

Conclusions:

  • Emerging therapies show promise for treating CRPC.
  • Targeted drug development is crucial for overcoming treatment resistance.
  • Ongoing clinical trials are vital for advancing CRPC care.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...